Individuals living in an onchocerciasis focus and treated three-monthly with ivermectin develop fewer new onchocercal nodules than individuals treated annually
- PMID: 32414398
- PMCID: PMC7229600
- DOI: 10.1186/s13071-020-04126-x
Individuals living in an onchocerciasis focus and treated three-monthly with ivermectin develop fewer new onchocercal nodules than individuals treated annually
Abstract
Background: Little information is available on the effect of ivermectin on the third- and fourth-stage larvae of Onchocerca volvulus. To assess a possible prophylactic effect of ivermectin on this parasite, we compared the effects of different ivermectin regimens on the acquisition of onchocercal nodules.
Methods: We analyzed data from a controlled randomized clinical trial of ivermectin conducted in the Mbam Valley (Cameroon) between 1994 and 1998 in a cohort of onchocerciasis infected individuals. The number of nodules that appeared between the start and the end of the clinical trial was analyzed, using ANOVA and multivariable Poisson regressions, between four treatment arms: 150 µg/kg annually, 800 µg/kg annually, 150 µg/kg 3-monthly, and 800 µg/kg 3-monthly.
Results: The mean number of nodules that appeared during the trial was reduced by 17.7% in subjects treated 3-monthly compared to those treated annually (regardless of the dose). Poisson regression model, adjusting on subject's age and weight, initial number of nodules and intensity of O. volvulus infection in his village of residence, confirmed that the incidence of new nodules was reduced in 3-monthly treatment arms compared to annually treatment arms, and that the dosage of ivermectin does not seem to influence this effect. Furthermore, the number of newly acquired nodules was positively associated with the initial number of nodules. Analysis of disappearance of nodules did not show any significant difference between the treatment groups.
Conclusions: To our knowledge, these results suggest for the first time in humans, that ivermectin has a partial prophylactic effect on O. volvulus. Three-monthly treatment seems more effective than annual treatment to prevent the appearance of nodules.
Keywords: Cameroon; Ivermectin; Nodules; Onchocerca volvulus; Onchocerciasis; Onchocercoma.
Figures
Similar articles
-
Individual host factors associated with Onchocerca volvulus microfilarial densities 15, 80 and 180 days after a first dose of ivermectin.Acta Trop. 2011 Sep;120 Suppl 1:S91-9. doi: 10.1016/j.actatropica.2010.05.004. Epub 2010 May 24. Acta Trop. 2011. PMID: 20497765 Clinical Trial.
-
Reproductive status of Onchocerca volvulus after ivermectin treatment in an ivermectin-naïve and a frequently treated population from Cameroon.PLoS Negl Trop Dis. 2014 Apr 24;8(4):e2824. doi: 10.1371/journal.pntd.0002824. eCollection 2014 Apr. PLoS Negl Trop Dis. 2014. PMID: 24762816 Free PMC article.
-
A randomized, double-blind, controlled trial of the effects of ivermectin at normal and high doses, given annually or three-monthly, against Onchocerca volvulus: ophthalmological results.Trans R Soc Trop Med Hyg. 2005 Apr;99(4):279-89. doi: 10.1016/j.trstmh.2004.04.003. Trans R Soc Trop Med Hyg. 2005. PMID: 15708387 Clinical Trial.
-
Doxycycline plus ivermectin versus ivermectin alone for treatment of patients with onchocerciasis.Cochrane Database Syst Rev. 2016 Jan 15;2016(1):CD011146. doi: 10.1002/14651858.CD011146.pub2. Cochrane Database Syst Rev. 2016. PMID: 26771164 Free PMC article. Review.
-
Elimination of human onchocerciasis: history of progress and current feasibility using ivermectin (Mectizan(®)) monotherapy.Acta Trop. 2011 Sep;120 Suppl 1:S100-8. doi: 10.1016/j.actatropica.2010.08.009. Epub 2010 Aug 27. Acta Trop. 2011. PMID: 20801094 Review.
Cited by
-
Can mass drug administration of moxidectin accelerate onchocerciasis elimination in Africa?Philos Trans R Soc Lond B Biol Sci. 2023 Oct 9;378(1887):20220277. doi: 10.1098/rstb.2022.0277. Epub 2023 Aug 21. Philos Trans R Soc Lond B Biol Sci. 2023. PMID: 37598705 Free PMC article.
-
Disease perception, impacts and coping strategies for onchocerciasis in Southeast Nigeria: a qualitative study among patients and program managers.BMC Public Health. 2023 May 10;23(1):841. doi: 10.1186/s12889-023-15821-6. BMC Public Health. 2023. PMID: 37165379 Free PMC article.
-
Evaluating the impact of alternative intervention strategies in accelerating onchocerciasis elimination in an area of persistent transmission in the West Region of Cameroon.PLoS Negl Trop Dis. 2022 Dec 21;16(12):e0010591. doi: 10.1371/journal.pntd.0010591. eCollection 2022 Dec. PLoS Negl Trop Dis. 2022. PMID: 36542603 Free PMC article.
-
Current Use of Ivermectin in Dermatology, Tropical Medicine, and COVID-19: An Update on Pharmacology, Uses, Proven and Varied Proposed Mechanistic Action.Indian Dermatol Online J. 2021 Jul 14;12(4):500-514. doi: 10.4103/idoj.idoj_298_21. eCollection 2021 Jul-Aug. Indian Dermatol Online J. 2021. PMID: 34430453 Free PMC article. Review.
-
Drugs that target early stages of Onchocerca volvulus: A revisited means to facilitate the elimination goals for onchocerciasis.PLoS Negl Trop Dis. 2021 Feb 18;15(2):e0009064. doi: 10.1371/journal.pntd.0009064. eCollection 2021 Feb. PLoS Negl Trop Dis. 2021. PMID: 33600426 Free PMC article.
References
-
- Lämmler G. Experimental chemotherapy and chemoprophylaxis of filariasis. Pestic Sci. 1977;8:563–576. doi: 10.1002/ps.2780080523. - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
